According to a newly published market research report by 24LifeSciences, global varicella vaccine market was valued at USD 4.13 billion in 2024 and is projected to reach USD 7.20 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.4% during the forecast period 2025–2032. Varicella vaccine, clinically known as the chickenpox vaccine, is a highly effective...

North America holds a significant share of the inactivated vaccines market due to high vaccination coverage, established healthcare systems, and strong government support for immunization initiatives. Growing awareness of preventive healthcare, continuous vaccine innovation, and increasing efforts to control infectious diseases are expected to support market expansion across the region. The...